POP Biotechnologies and EuBiologics’ EuCorVac-19 COVID-19 Vaccine Hits Target in Phase 3 Trial
POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical startup, announces top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine...
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Dermata raised $5 million gross proceeds from a public offering in March 2023 -- Dermata submitted an End of Phase 2 meeting package to...
Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies-- Dermata also submitted an end of phase 2 meeting...
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
- End of Phase 2 meeting with FDA for DMT310 for moderate-to-severe acne expected in 2Q 2023 -- Initiation of DMT310 Phase 3 clinical trial...
Neumentum Announces Initiation of Phase 3 Program Evaluating Its Lead Product Candidate, NTM-001, for the Management of Moderately Severe Acute Pain
NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for 24h Continuous Infusion. NTM-001 has the Potential to Deliver Opioid-Level Pain...